Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Unlicensed Stem Cell Clinics Are 'Surrogate' For Right To Try, US FDA's Marks Says

Executive Summary

CBER director said unlicensed stem cell clinics often report adverse events not made public, which is a concern under Right To Try.

Related Content

Expanded Access: US FDA Told To Increase Regulatory Clarity, Early Interactions With Sponsors
US FDA's Woodcock: Sponsors Have To Make Right-To-Try Decisions
US FDA Right To Try Policy: For Now, Defer Questions To Sponsors, Bill Text
Right-To-Try Bill Heads To White House, Putting Firms In Driver's Seat
Lutathera’s Broad Tumor Indication Aided By Expanded Access Data
Right-To-Try Opponents Brace For Last Chance To Stop Bill
Regenerative Medicines Provisions Of Cures Act A Top Priority For CBER


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts